This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects with F2 or F3 fibrosis (NASH CRN system). Antifibrotic biomarker activity will be evaluated on an exploratory basis.
1 Primary · 6 Secondary · Reporting Duration: dosing period of 1 year with 1 month observation and follow up period
336 Total Participants · 4 Treatment Groups
Primary Treatment: Cohort C: Rencofilstat 225 mg · Has Placebo Group · Phase 2
Age 18 - 75 · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: